OncoQuest Inc. is a pioneering biotechnology company specializing in immuno-oncology, dedicated to developing combination therapies that utilize proprietary antibodies to activate the immune system. Headquartered in Canada and a subsidiary of Quest Pharmatech, OncoQuest focuses on creating synergistic treatments by combining its novel antibodies with chemotherapeutics and other immunomodulatory agents. These therapies aim to stimulate the proliferation of antigen-specific T cells, thereby improving clinical outcomes for a broad range of cancers, including ovarian cancer, where their lead investigational drug, Oregovomab, is in Phase 2 clinical trials. The company operates in the biotechnology sector, targeting healthcare providers and research institutions as its primary clients. OncoQuest's business model revolves around clinical development and eventual commercialization of its antibody-based therapies, generating revenue through partnerships, licensing agreements, and direct sales upon regulatory approval. The market it serves is the global oncology therapeutics market, which is driven by the increasing prevalence of cancer and the demand for more effective treatments.

Keywords: immuno-oncology, antibodies, cancer treatment, biotechnology, clinical trials, Oregovomab, T cells, chemotherapeutics, immunomodulatory, oncology therapeutics.